| Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| 13F holders | Current |
|---|---|
| Total holders | 211 |
| Opened positions | 38 |
| Closed positions | 35 |
| Increased positions | 93 |
| Reduced positions | 51 |
| 13F shares | Current |
|---|---|
| Total value | 2.99 tn |
| Total shares | 287.16 mm |
| Total puts | 385.60 k |
| Total calls | 258.40 k |
| Total put/call ratio | 1.5 |
| Largest owners | Shares | Value |
|---|---|---|
| GenScript Biotech | 174.50 mm | $0.00 |
| FMR | 13.45 mm | $437.57 bn |
| Hillhouse Capital Management | 13.05 mm | $725.34 mm |
| Ra Capital Management | 7.51 mm | $244.28 bn |
| T. Rowe Price | 6.81 mm | $221.54 mm |
| Hillhouse Capital Advisors | 5.98 mm | $194.74 bn |
| Westfield Capital Management | 5.71 mm | $185.92 bn |
| BlackRock | 4.61 mm | $149.96 bn |
| Suvretta Capital Management | 3.50 mm | $113.77 bn |
| IVZ Invesco | 3.31 mm | $107.71 bn |
